# OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)

> **NCT04283227** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Orchard Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Lysosomal Storage Diseases
- Metachromatic Leukodystrophy

## Interventions

- **GENETIC:** OTL-200

## Key facts

- **NCT ID:** NCT04283227
- **Lead sponsor:** Orchard Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-17
- **Primary completion:** 2026-01-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283227, "OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04283227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*